[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@DFCapodanno Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1103353352468025346.png) @DFCapodanno Davide Capodanno

Davide Capodanno posts on X about balloons the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

### Engagements: XXXXX [#](/creator/twitter::1103353352468025346/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1103353352468025346/c:line/m:interactions.svg)

- X Week XXXXXX -XX%
- X Month XXXXXX +1,222%
- X Months XXXXXX -XX%
- X Year XXXXXXX -XX%

### Mentions: X [#](/creator/twitter::1103353352468025346/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1103353352468025346/c:line/m:posts_active.svg)

- X Week X +33%
- X Month X +60%
- X Months XX -XXXX%
- X Year XX +27%

### Followers: XXXXXX [#](/creator/twitter::1103353352468025346/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1103353352468025346/c:line/m:followers.svg)

- X Week XXXXXX +0.17%
- X Month XXXXXX +0.71%
- X Months XXXXXX +4.20%
- X Year XXXXXX +9.30%

### CreatorRank: XXXXXXX [#](/creator/twitter::1103353352468025346/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1103353352468025346/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1103353352468025346/influence)
---

**Social topic influence**
[balloons](/topic/balloons)
### Top Social Posts [#](/creator/twitter::1103353352468025346/posts)
---
Top posts by engagements in the last XX hours

"I wouldnt exactly call myself a black belt in beta-blockers but with all this talk of superiority "non-superiority" and "non-non-inferiority" its really enough to get confused. If I interpret correctly the avalanche of trials from the past year accompanied by the inevitable meta-analysis the takeaway seems to be that after a myocardial infarction in patients with LVEF XX% those already on a beta-blocker shouldnt stop it and those not on one might benefit in the 4049% range MAYBE and hardly beyond 50%. Better go back to antithrombotics which are simpler"  
[X Link](https://x.com/DFCapodanno/status/1978180021111124265) [@DFCapodanno](/creator/x/DFCapodanno) 2025-10-14T19:24Z 21.5K followers, 18.3K engagements


"The most anticipated trial at next #TCT2025 is SELUTION DeNovo. So lets take a closer look. This study represents an important crossroads for drug-coated balloons (DCBs) in de novo lesions sinceapart from small vesselsthe results so far have been far from impressive. Lets start with the study population which includes patients with at least one vessel to be treated ranging from X to X mm in diameter. This means that some vessels would typically be treated with a DCB while others would more commonly receive a drug-eluting stent (DES). Naturally a proportion of patients initially intended for"  
[X Link](https://x.com/DFCapodanno/status/1979845384315785636) [@DFCapodanno](/creator/x/DFCapodanno) 2025-10-19T09:41Z 21.5K followers, 3552 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@DFCapodanno Davide Capodanno

Davide Capodanno posts on X about balloons the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

X Week XXXXXX -XX%
X Month XXXXXX +1,222%
X Months XXXXXX -XX%
X Year XXXXXXX -XX%

Mentions: X #

X Week X +33%
X Month X +60%
X Months XX -XXXX%
X Year XX +27%

Followers: XXXXXX #

X Week XXXXXX +0.17%
X Month XXXXXX +0.71%
X Months XXXXXX +4.20%
X Year XXXXXX +9.30%

CreatorRank: XXXXXXX #

Social Influence #

Social topic influence balloons

Top Social Posts #

Top posts by engagements in the last XX hours

"I wouldnt exactly call myself a black belt in beta-blockers but with all this talk of superiority "non-superiority" and "non-non-inferiority" its really enough to get confused. If I interpret correctly the avalanche of trials from the past year accompanied by the inevitable meta-analysis the takeaway seems to be that after a myocardial infarction in patients with LVEF XX% those already on a beta-blocker shouldnt stop it and those not on one might benefit in the 4049% range MAYBE and hardly beyond 50%. Better go back to antithrombotics which are simpler"
X Link @DFCapodanno 2025-10-14T19:24Z 21.5K followers, 18.3K engagements

"The most anticipated trial at next #TCT2025 is SELUTION DeNovo. So lets take a closer look. This study represents an important crossroads for drug-coated balloons (DCBs) in de novo lesions sinceapart from small vesselsthe results so far have been far from impressive. Lets start with the study population which includes patients with at least one vessel to be treated ranging from X to X mm in diameter. This means that some vessels would typically be treated with a DCB while others would more commonly receive a drug-eluting stent (DES). Naturally a proportion of patients initially intended for"
X Link @DFCapodanno 2025-10-19T09:41Z 21.5K followers, 3552 engagements